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Abstract 
Epidemiologic and experimental studies suggest that dietary fatty acids influence the development 
and progression of breast cancer. However no clear data are present in literature that could 
demonstrate how n-3 PUFA can interfere with breast cancer growth. It is suggested that these fatty 
acids might change the structure of cell membrane, especially of lipid rafts. During this study we 
treated MCF-7 and MDA-MB-231 cells with AA,EPA and DHA to asses if they are incorporated in 
lipid raft phospholipids and are able to change chemical an physical proprieties of these structures. 
Our data demonstrate that PUFA and their metabolites are inserted with different yield in cell 
membrane microdomains and are able to alter fatty acid composition without decreasing the total 
percentage of saturated fatty acids that characterize these structures. In particular in MDA-MB-231 
cells, that displays the highest content of Chol and saturated fatty acids, we observed the lowest 
incorporation of DHA, probably for sterical reasons; nevertheless DHA was able to decrease Chol 
and SM content. Moreover PUFA are incorporated in breast cancer lipid rafts with different 
specificity for the phospholipids moiety, in particular PUFA are incorporated in PI, PS and PC 
phospholipids that may be relevant to the formation of PUFA metabolites (prostaglandins, 
prostacyclins, leukotrienes, resolvines and protectines) of phospholipids deriving second 
messengers and signal transduction activation. The bio-physical changes after n-3 PUFA incubation 
have also been highlighted by Atomic Force Microscopy. In particular, for both cell lines the DHA 
treatment produced a decrease of the lipid rafts in the order of about 20%-30%. It is worth noticing 
that after DHA incorporation lipid rafts exhibit two different height ranges. In fact, some lipid rafts 
have a higher height of 6-6.5 nm. In conclusion n-3 PUFA are able to modify lipid raft  biochemical 
and biophysical features leading to decrease of breast cancer cell proliferation probably through 
different mechanisms related to acyl chain length and unsaturation. While EPA may contribute to 
cell apoptosis mainly through decrease of AA concentration in lipid raft phospholipids, DHA may 
change the biophysical properties of lipid rafts decreasing the content of cholesterol and probably a 
redistribution of key proteins. 
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1. Introduction 
The term omega-3 fatty acids (n-3 or -3) refers to a class of polyunsaturated fatty acids (PUFA) 
having the last double bond in the n-3 position. The main dietary sources of eicosapentaenoic (EPA, 
20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) are cold-water fish oils. Epidemiological 
studies have suggested that an increased n-3 PUFA intake might be associated with a reduced breast 
cancer incidence in humans [1-3]. A number of mechanisms have been proposed for the anticancer 
actions of n-3 PUFA, including suppression of neoplastic transformation, inhibition of cell 
proliferation, enhancement of apoptosis, and antiangiogenic action. Most of these mechanisms have 
been directly or indirectly linked to their inhibition of the production of eicosanoids from n-6 
PUFA. In addition, it has also been suggested that these fatty acids might change the fluidity and 
structure of cell membrane, especially of lipid rafts.  The plasma membrane is involved in almost 
all aspects of cell biology, including morphogenesis, proliferation, migration, invasion, 
transformation, differentiation, secretion and apoptosis. Numerous experimental data indicate that 
the presence of PUFA in the membrane bilayer might determine dramatic changes in physical-
chemical properties [4-5], a significant lowering of cholesterol solubility [6], and changes in the 
activity of transmembrane proteins such as the G-protein coupled membrane receptors [7-8]. In fact 
the structure and dynamics of these polyunsaturated chains at the molecular level are profoundly 
different from their saturated counterpart, with very short reorientational correlation times and 
extremely low chain order.   
In the past two decades, a growing number of data indicate that membrane lipids exist in gel, liquid-
ordered or liquid-disordered states, depending on the complex environment of the cell. 
Subsequently, a lipid raft theory evolved in which liquid-ordered microdomains or lipid rafts, are 
floating over the “sea” of bulk membrane, which is in a liquid-disordered state. The preponderance 
of saturated hydrocarbon chains in sphingolipids allows for tight cholesterol interaction, thereby 
forming a “packed” liquid-ordered phase [9-10]. Lipid rafts can be classified as morphologically 
featureless, detergent-resistant membranes (DRMs) due to their insolubility in cold non ionic 
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detergents [11]. These domains are characterized physicochemically by a relative rigidity and 
reduced fluidity compared with the surrounding plasma membrane, which is in part caused by their 
cholesterol content [12-14]. Lipid rafts are highly dynamic and may rapidly assemble and 
disassemble, leading to a dynamic segregation of proteins [12, 15]. In fact rafts localization is 
shown to modulate a variety of proteins, such as receptor activities and therefore signal transduction 
[16, 17]. Cholesterol alterations, which affect raft structure, also might alter the receptor function 
[16]. For example, it is now known that T cell intracellular signalling cascades, endocytosis, protein 
trafficking, and cell-cell communication are modulated in part by altering the lipid-protein 
composition of the bulk membrane and specialized lipid microdomains [18, 19]. 
In the present paper, we analyzed the incorporation of PUFA in cancer cell lipid rafts by HPLC/GC 
analysis of raft phospholipid fatty acid composition. In addition, morpho-dimensional changes in 
lipid rafts have been visualized and evaluated by atomic force microscopy (AFM) studying purified 
membrane samples both before and after the n-3 PUFA treatment. AFM technique allows obtaining 
three-dimensional images of the surface topography of biological specimens (i.e. lipid 
microdomains) at nanometer resolution in a physiological-like environment thus providing 
structural/functional insights that cannot be obtained with more conventional approaches. 
 
2. MATERIALS AND METHODS 
2.1. Materials 
EPA (cis-5,8,11,14,17-eicosapentaenoic acid sodium salt), DHA (cis-4,7,10,13,16,19-
docosahexaenoic acid sodium salt) and AA (cis-5,8,11,14-arachidonic acid sodium salt) were 
purchased from Sigma-Aldrich, US. PUFA are dissolved in ethanol and stored at -80°C under 
N2(g). The rabbit polyclonal anti-flotillin-1 and the mouse monoclonal anti-clathrin heavy chain 
(HC) antibody were purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA. Bound 
primary antibody is visualized by proper secondary horseradish peroxidase (HRP)-linked antibody, 
purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA. 
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2.2. Cell lines and culture conditions 
Human breast cancer cells MDA-MB-231 (ER-negative) and MCF7 (ER-positive) were kindly 
provided by IST (Italian National Cancer Research Institute, Genova Italy, laboratory of Molecular 
Mutagenesis and DNA repair, Dr. Degan). Both cell lines derive from human mammary 
adenocarcinoma; MCF7 line retains several characteristics of differentiated mammary epithelium 
including ability to process estradiol via cytoplasmic estrogen receptors. The MDA-MB-231 cells 
over-express the receptor of epidermal growth factor (EGFR). 
Both cell lines are routinely maintained in DMEM medium (Gibco-BRL, Life Tecnologies Italia srl, 
Italy) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml 
streptomycin and 2 mM glutamine.  
During treatments the culture medium contains 10% fetal bovine serum (FBS) (medium for 
treatments). Cells are grown at 37°C in 5% CO2 at 98% relative humidity. 
2.3. Lipid rafts isolation 
Previous experiments with MDA-MB-231 and MCF7 cells allowed us to determine the 
concentrations of EPA (230 M) and DHA (200 M), required to inhibit cell growth by 20%-30%. 
In both cell lines AA is used at the concentration of 200 M, without inducing cell death [20]. 
 Cells are seeded at 1.5x10
4
 cells/cm
2
 for MDA-MB-231 and 3x10
4
cells/cm
2
 for MCF7 in 18 ml of 
medium containing 10% v/v FBS for 48 hrs to adhere. After 48 hrs, medium is replaced with fresh 
medium containing the experimental fatty acids (AA, EPA or DHA). Cells are treated for 72 hrs. 
Experiments include control cells, which are not exposed to any exogenous fatty acids, but to equal 
concentration of ethanol. After treatment cells are harvested by scrapering in phosphate-buffered 
saline containing 0.4 mM Na3VO4. Cells are then centrifuged and suspended in 1.4 ml lysis buffer 
(1% Triton X-100, 10 mM Tris buffer, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM 
phenylmethylsulfonyl fluoride, 75 milliunits/ml aprotinin), allowed to stand on ice for 20 min, and 
finally treated with Dounce homogenizer (10 strokes, tight).   
To isolate lipid rafts cell lysate is centrifuged (5 min at 1,300xg) and the supernatant is transferred 
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to eppendorf tubes. 1 ml of lysate is mixed in ultracentrifuge tubes (Beckman Coulter) with equal 
volume of 85% sucrose (w/v) in 10 mM Tris buffer, pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1 
mM Na3VO4, and then overlaid with 5.5 ml of 30% w/v sucrose (in the previous buffer) and 4 mL 
of 5% w/v sucrose. Tubes are centrifuged at 200,000xg; 17 hrs at 4° C (Optimal LE-80K 
Ultracentrifuge, Beckman Coulter). After centrifugation 11 fractions are collected; to confirm the 
location of lipid rafts, the content of cholesterol (Chol), sphingomyelin (SM), gangliosides, flotillin-
1 and clathrin HC is determined in each fraction by HP-TLC and Western Blot.  Lipid rafts are 
usually isolated in 5 and 6 fractions.  
2.4. Lipid extraction 
Fractionated cell membranes were extracted with three different chloroform/methanol mixtures 1:1, 
1:2, 2:1 (v/v) and partitioned chloroform/methanol/water, 47:48:1, v/v/v and then with water. The 
organic phase, after partitioning, is dried and resuspended in chloroform/methanol (2:1) for the 
analysis of phospholipids, gangliosides and cholesterol content. 
2.5 Characterization of Lipid Rafts  
Free Chol and SM were separated by HP-TLC using silice gel HPTLC plates (Merck, Darmstadt, 
Germany).  Chromatography was performed in hexane/ether/glacial acetic acid (90:10:1 by volume) 
and with chloroform/methanol/glacial acetic acid/water (60:45:4:2 by volume), respectively. Chol 
was visualized with a solution of copper sulphate in phosphoric acid at 180 °C, while SM with 
anisaldehyde in acetic acid and sulphuric acid at 120 °C. Chol and SM standards were spotted on 
the same plate. 
While polar glycosphingolipids, contained in the upper phase, were always separated by HP-TLC 
using silice gel plates. Chromatography was performed in chloroform/methanol/0.25% aqueous 
CaCl2 (5:4:1 v/v/v). Plates were the air dried and gangliosides visualized with resorcinol at 120°C. 
Ganglioside standards were spotted on the same plate. 
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For protein characterization of lipid rafts, all fractions were resolved on sodium dodecyl sulphate-
polyacylamide gel electrophoresis (SDS-PAGE) and incubated with different antibodies to raft 
(flotillin-1) and non-raft (clathrin HC) markers [21].  
Equal volumes of all fractions were resuspended in SDS loading buffer and boiled at 100°C for 5 
min to avoid to protein aggregates. Protein contents were quantified by Lowry assay [22].  Samples 
were run on SDS-PAGE, transferred to polyvinylidene fluoride (PVDF) transfer membranes. 
Membranes were first incubated with rabbit polyclonal anti-flotillin-1 antibody (1:200) and then 
incubated with the corresponding horseradish peroxidise (HRP)-linked secondary antirabbit 
antibody. Afterward, the same membrane was successively reblotted with the antibody specifically 
directed to clathrin HC, followed by incubation with the corresponding HRP-linked secondary 
antibody.  
Finally, the specific antibody signals were visualized by using the enhanced chemiluminescence 
(ECL-PLUS, Perkin Elmer, USA ), followed by autoradiography. 
2.6 Analysis of different classes of lipid rafts PLs and cholesterol  
Purification and quantitative analysis of membrane phospholipids and cholesterol is obtained using 
a HPLC-ELSD system (Jasco, Japan; Sedex SEDERE, FR) equipped with a LiChrospher Si 60 
column (LiChroCART 250-4, Merck, Darmstadt, Germany). 
The chromatographic separation is carried out as previously described [20]. Evaporative Light 
Scattering Detector (ELSD) is used to detect and quantify separated PL species, in comparison with 
calibration standard curves. 
After elution, samples are splitted in two aliquots. The ratio is 1:9, i.e. one part to the detector and 
nine parts are collected by Gilson Fraction Collector Model 201, in order to separate the different 
phospholipid classes for further GC analysis.  
After separation, each phospholipid class is analysed for fatty acid composition by GC in following 
conditions.  
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Fatty acid methyl esters are obtained by transesterification with sodium methoxide in methanol 
3.33% w/v and injected into Agilent (Agilent Technologies 6850 Series II) gaschromatograph, 
equipped with a flame ionization detector (FID) under the following experimental conditions: 
capillary column: AT Silar length 30 m, film thickness 0.25 M. Gas carrier: helium, temperature 
Injector 250°C, detector 275°C, oven 50°C for 20 min, rate of 10°C min 
-1
 until 200°C for 20 min. 
2.7. AFM imaging  
For AFM imaging, purified membrane samples, namely the fraction 5 obtained by the 
ultracentrifugation process described above, were diluted 1:30 in a adsorption buffer (150 mM KCl, 
25 mM MgCl2, 10 mM Tris/HCl pH 7.5). 50 µL of the solution is floated on a freshly cleaved mica 
leaf and let adhered for 10 minutes. Then, sample is gently rinsed three times with a recording 
buffer (150 mM KCl, 10 mM Tris/HCl pH 7.5) to remove membranes that have not been strongly 
adsorbed to the mica support. A drop of 70 μl of recording buffer is placed on the mica support 
before AFM imaging.  
AFM imaging is performed using a Multimode Nanoscope IIId (Veeco, Santa Barbara, CA, USA) 
equipped with a 12 µm scanner and sharpened Si3N4 cantilevers with a constant spring of 0.06 N/m 
and a 10 nm curvature radius (Veeco, Santa Barbara, CA, USA). The AFM is operated in contact 
mode in constant force conditions. The set point is manually adjusted and kept as low as possible to 
obtain the best resolution while the total force applied on the sample during the imaging is 
approximately 300 pN as measured by force–distance curve. The 512x512 pixel2 images are 
recorded at typical scan frequencies of 4-6 Hz. AFM images are flattened using the SPMLab NT 
Ver. 6.0.2 software (Veeco, Santa Barbara, CA, USA). 
 
3. RESULTS 
3.1. Characterization of Lipid Rafts from human breast cancer cells 
We first tested the purity of lipid rafts isolated from human breast cancer cells, MDA-MB-231 and 
MCF7 cells, using lipid and protein raft and non-raft markers.  
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The purification of microdomains was demonstrated by the enrichment of specific phospholipids, 
especially sphingomyelin, cholesterol and gangliosides, in particular GM1. Lipid rafts are usually 
isolated in fractions 5 and 6 in all treated and untreated cells (Fig. 1).  
Thus, specific antibody directed to lipid raft marker, flotillin-1, was used to identified raft-enriched 
fractions, observing that this marker was mostly present in fractions 5 and 6 (Fig. 1). The same 
membranes were then used to reblot with antibody directed to clathrin HC, a protein highly 
represented in no raft fractions of plasma membrane [21], observing that this antibody recognized 
some bands especially in fraction 11 (Fig. 1). No significant differences are visualized between the 
different treatments and control cells. 
3.2. Incorporation of  PUFA in lipid rafts of breast cancer cells After raft isolation we analyzed 
by gas chromatography the fatty acid profile of total cell lipid extract, of cell phospholipids and of 
the raft fractions obtained from both treated and untreated cells.  
Even if no radiolabel compounds were used, we calculated the percentage of PUFA incorporated 
into cell lipids. Data are reported in Table 1; it is possible to observe that MCF-7 incorporate an 
higher percentage of PUFA compared to MDA-MB-231 cells. In both cell lines the increase of 
length and double bounds of the fatty acid corresponds to a decreased incorporation. In particular 
in both cell lines the amount of incorporated DHA in lipid rafts is lower (about a third) compared 
to the amount of AA (1% in MCF-7 and 0.37 % in MDA-MB-231 of total PUFA administered).  
As shown in Table 2, when both cell lines are treated with n-3 PUFA or n-6 PUFA, the total fatty 
acid composition of membrane lipid raft changes. The treatment with AA determines a significant 
increase of this FA from 4.29% to 13.27% in MDA-MB-231 cells and from 8.46% to 20.65% in 
MCF7 cells. Also the total n-6 PUFA content is significantly increased. Furthermore the data show 
also a significant reduction of  n-3 PUFA, included EPA, DPA and DHA.  
The incubation with EPA induces a significant increase of this FA from 0.74% to 6.14% in MDA-
MB-231 cells and from 0.77% to 12.91% in MCF7 cells, and of total n-3 PUFA content. On the 
contrary we have verified a reduction of total n-6 PUFA, in particular of AA, in both cell lines 
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after EPA treatment.  Unexpectedly we found an interesting increase also of docosapentaenoic acid 
(DPA) content, from 0.33% to 4.60% in MDA-MB-231and from 0.46% to 3.59% in MCF-7 
microdomains. 
The treatment with DHA causes in both cell lines a significant increase of C22:6 n-3, and of EPA. 
At the same time, the results show a reduction of AA only in MDA-MB-231 cells. 
Worth of note is that the percentage of saturated fatty acids is not changed by PUFA treatment and 
is higher for MDA-MB-231  (around 70%) in comparison to MCF-7 (around 45%). 
From these data it is possible to observe that PUFA are all incorporated in cell membrane 
microdomains even if with different degrees.  
3.3. Changes of fatty acid composition in different phospholipid species of lipid rafts after 
treatment with n-3 and n-6 PUFA  
To detect if PUFA treatment induces specific changes in fatty acid composition of raft 
phospholipids, we have purified raft phospholipids and analyzed their fatty acid composition. 
Table 3 refers to polyunsaturated fatty acid composition of microdomains phospholipids isolated 
from MDA-MB-231 cells. After AA treatment it is possible to detect an increase of C20:4 n-6 in 
PI, PS, PC, and SM, while the concentration of AA in PE does not change; also in MCF7 
microdomains (see Table 4), the AA treatment determines an enrichment of this FA, especially in 
PI, PS, PC and SM. The treatment with EPA induces an increase of C20:5 n-3 in all PLs but not in 
SM in MDA-MB-231 as in MCF7 microdomains. Also the content of DPA, derived from EPA 
metabolism,  increases in PE, PS and PC of MDA-MB-231 rafts, but not in PI and SM, On the 
contrary in MCF7 rafts EPA improves in all phospholipids. This data is in agreement with Table 1 
that indicates an higher incorporation of EPA in phospholipids and raft of MCF-7 cells. 
Furthermore after EPA treatment the level of DHA, derived from its metabolism, increases in PI of 
MDA-MB-231 microdomains, while in MCF7 microdomains DHA increases in all PLs except in 
PI. The data indicate also a reduction of AA, and in general of n-6 PUFA, especially in PI, PS, and 
PC of MDA-MB-231 microdomains, and in PE and PS in MCF7 rafts. 
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The incubation with DHA determines its incorporations in all PLs of  both cell lines, a reduction of 
AA in PE and PI of MDA-MB-231 and in PI of MCF-7 microdomains. Moreover C22:6 n-3 causes 
a significant increase of EPA in all PLs but in PS of MDA-MB-231 rafts. However this enrichment 
induces a significant reduction of MUFA and SFA content especially in PI and PC of MDA-MB-
231 lipid rafts. 
3.4. Effects of PUFA incorporation on sphingomyelin and cholesterol content 
Collected data indicate that n-3 PUFA treatment modifies the content of sphingomyelin (SM). In 
particular DHA incubation significantly reduces SM in lipid rafts, but not in whole cells. Figure 2 
reports the relative content related to controls of SM after PUFA treatment. 
In particular in MCF7 microdomains DHA induces a reduction of SM  to about  50% (from 107.53 
to 48.51 nmol/mg Prot) and in MDA-MB-231-microdomains to 60% (from 244.22 to 162.35 
nmol/mg Prot.). EPA treatment induces a slight non significant reduction of SM only in MDA-MB-
231 lipid rafts (see Fig. 2b).  
On the contrary the AA treatment does not determine a reduction of this sphingolipid, in 
microdomains and in whole cells conversely it induces an increase that is not statistically significant 
due to the high variability of the data (see Fig. 2). We have also studied the effects of PUFA 
treatment on cholesterol content in breast cancer cell rafts. The data indicate that DHA determines a 
remarkable and significant reduction of this sterol, especially in MDA-MB-231 (from 829.39 to 
585.62 nmol/mg Prot.) (see Fig. 3b). In MCF7 cells the cholesterol reduction corresponds to -40%, 
from 208.88 to 150.28 nmol/mg Prot. (see Fig. 3a). Worth of note is that the content of both 
cholesterol and sphingomyelin are higher in MDA-MB-231 cells. 
The incubation with EPA determines a slight cholesterol reduction in MDA-MB-231 lipid rafts, to 
681.29 nmol/mg prot. (see Fig. 3b). 
Furthermore, the treatment with AA produces, in MDA-MB-231 lipid rafts a significant increase of 
cholesterol raising the content to 1033.24 nmol/mg Prot (see Fig. 3b).  
3.5. AFM investigation 
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Lipid rafts were also analyzed by means of AFM. In particular, AFM investigation allowed to 
relate chemical-physical modifications, induced in MCF7 and MDA-MB-231 lipid rafts by the 
DHA incubation, to their morpho-dimensional changes. In Fig. 4, as an example, two AFM 
topography images of MCF7 lipid rafts before (a) and after (b) DHA incorporation have been 
reported. The height profiles corresponding to the black lines drawn in Figs. 4a and 4b have been 
showed in Figs. 5a and 5b respectively. After DHA incorporation, AFM images clearly show a 
reduction of the number of lipid rafts (in the order of about 20-30%). Moreover, DHA treated lipid 
rafts show, on average, a lateral size larger than the control ones. In addition, interestingly the 
profile lines (see Fig. 5) show the presence, in the DHA incorporated rafts, of two different height 
ranges (4-4.5 nm and 6-6.5 nm). In particular, the 6 nm thickness of  lipid rafts could be produced 
by DHA incorporation effects. On the contrary, untreated lipid rafts show a constant height of 
about 4 nm as awaited for a membrane lipid bilayer. The same results have been obtained on 
MDA-MB-231 lipid rafts. 
Finally, high resolution AFM imaging, obtained visualizing nanometer scan areas, allowed to 
observe on the lipid raft surface of DHA treated MCF7 cells, pores with an average diameter of 
about 7 nm (see Fig. 6a). Although the data do not allow to identify the visualized structures, the 
pore diameter appears to be in good agreement with the dimensions of proteins observed by AFM 
on biological membranes. The histogram in Fig. 6b shows the measured values along and 
perpendicularly the scan direction obtained analysing the height profiles drawn in eleven AFM 
topography images. In particular, along the scan direction the pore lateral size showed a normal 
distribution centred on 9.5 ± 1.2 nm (mean ± SD, n =34) while in the perpendicular direction a 
normal distribution centred on  7.5 ± 0.8 nm (mean ± SD, n =34).  
 
4. DISCUSSION 
Dietary lipids are important for the integrity and functionality of cell membranes.  It is recognized 
that intake of n-3 PUFA can impact numerous processes in the body, including cancer, 
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cardiovascular, neurological and immune functions [23-25]. Many studies demonstrated that n-3 
PUFA act with synergy to anticancer drugs in cells culture or in tumor-bearing animals, decreasing 
tumor size, reducing side effects and prolonging survival [26-28].  
Lipid rafts are known to be rich in signalling molecules and to regulate signal transduction in 
normal and cancer cells activating or suppressing phosphorylation cascades related to growth, 
survival and many other physiological processes, mediated by membrane proteins such as Src, 
FAK, heterotrimeric G protein subunits and tyrosin kinases receptors as EGFR [29, 30].  
The key difference between the lipid rafts and the membrane bilayers from which they are formed is 
their lipid composition. Rafts contain cholesterol and sphingolipids at concentrations up to 50% 
higher than rest of the membrane. The hydrophobic alkyl chains of lipids within the rafts are more 
saturated compared to the surrounding bilayer and hence tightly packed [31-33].  
Our study was aimed to understand if the omega-3 effects on cancer cells may be related to 
alteration of biochemical and biophysical characteristics of lipid rafts.  
We used different long chain PUFA in relative high concentration, due to the fact that in our 
condition the cells are relatively resistant to fatty acid treatment. 
The PUFA concentration of human blood may vary according to age, sex, genetics, diseases and 
dietary habits [34]. Recent reports  from the EPIC-Norfolk cohort study showed that the average 
concentrations of EPA, DHA in plasma are 56.1 and 236.2 µmol/L respectively with a high 
individual variability [35].  
These data demonstrate that in vivo the doses used in our study can be reached and in some case are 
relative normal. Moreover observations also from our laboratory indicate very low levels of omega-
3 PUFA in blood of breast and colon cancer patients [36]. 
In literature there are different reports about cancer cells treatment with different protocols for 
PUFA administration and different dosages are reported ranging from 10-200 µM for different 
times, from 24hrs to 8 days of treatment. These differences may be due to the fatty acid solubility in 
different mediums, mixture of PUFA, type of employed reagent and their relative purity (i.e. free 
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fatty acid, sodium salt, ethyl esters,  TGs, solubilised with serum or precharged on albumin or 
LDL). 
As our goal was to induce fatty acid incorporation within lipid raft; we used fatty acid sodium salts 
solubilised in medium containing 10% serum. In these conditions the cells are alive around 80% 
after 72 hrs of treatment [20] and were able to incorporate fatty acids, to metabolize them and to 
insert them into cell membrane lipid rafts, as indicated by present data. The existence of  elongases 
and desaturases able to metabolize PUFA is reported in many tumor cells [37].  
In fact our data demonstrate that PUFA and their metabolites are inserted with different yield in cell 
membrane microdomains and are able to alter fatty acid composition without decreasing the total 
percentage of saturated fatty acids that characterize these structures. In particular in MDA-MB-231 
cells, that displays the highest content of Chol and saturated fatty acids, we observed the lowest 
incorporation of DHA, probably for sterical reasons; nevertheless DHA was able to decrease Chol 
and SM content. 
Some epidemiological studies addressed the hypothesis that it is possible to correlate breast cancer 
incidence with Stearoyl-CoA desaturase (SCD-1) expression and activity. Low SCD-1 activity is 
associated with decreased risk of breast cancer, and it is hypothesized that it can be measured by 
substrate to product ratios such as the saturation index measured in blood, or plasma or erythrocyte 
membrane as C16:0/C16:1 or C18:0/C18:1. 
For instance in the Italian population [38] it was demonstrated a positive correlation between 
saturation index and protection from breast cancer. 
Interestingly previous results from our lab [20] demonstrated that  MCF-7 and MDA-MB231 cell 
membrane are rich of oleic acid with a very low saturation index around 0.5. 
In this study we isolated lipid raft that, as their nature, are very rich in saturated fatty acids. 
Nevertheless, while in MDA-MB-231 saturation index of the rafts is around 4, MCF-7 express a 
saturation index less than 1 with high levels of monounsaturated fatty acids. This may indicate that 
these cell lines may be different sensible to new therapeutic approaches using SCD-1 inhibitors 
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[39].  In fact AA, EPA and DHA increase the saturation index only in MCF-7 cells while low 
changes are recorded in MDA-MB-231 cells. Moreover omega-6 and omega-3 PUFA may have 
different regulatory effects on SCD-1 gene expression as already demonstrated in animal models 
[40, 41]. Further and finalized experiments are needed to address this issue. We have also analyzed 
the changes in content of sphingomyelin and cholesterol in breast cancer cell rafts after PUFA 
treatment. In particular, we have observed that DHA determines a reduction of SM content in lipid 
rafts of both cell lines.  
These reductions might be due to an activation of sphingomyelinase (SMase). SMase is an enzyme 
that catalyzes the hydrolysis  of SM to ceramide. A variety of studies have shown that the ceramide 
is ubiquitously produced during cellular stress and is associated with apoptosis [42, 43]. The neutral 
SMase (N-SMase) is a plasma membrane-bound enzyme that is implicated in mediating apoptosis 
and it resides in lipid rafts [44]. Therefore factors influencing the lipid composition of membranes 
can influence the activity and distribution of N-SMase in microdomains. Wu et al. already 
demonstrated that in Jurkat leukemic cells, EPA and DHA increase the N-SMase activity inducing 
SM  hydrolysis [45], our data are in agreement with these observations.  
We also showed that DHA, more than EPA, determines a reduction of cholesterol in lipid rafts of 
breast cancer, especially in MDA-MB-231 cells. 
Cholesterol is the dynamic “glue” that holds the rafts together. Due to the rigid nature of the sterol 
group, cholesterol partitions preferentially into the lipid rafts where acyl chains of the lipids tend to 
be more rigid and in a less fluid state. It should be noted that cholesterol has the ability to pack in 
between the lipids in microdomains, serving as a molecular spacer and filling any voids between 
associated sphingolipids. It therefore plays a very important and dominant role in raft formation and 
stabilization [9, 31, 46]. Besides, cholesterol is known to play a important role in maintaining 
membrane integrity, trafficking, signal transduction and fluidity [31, 32]. Cholesterol depletion 
results in the disorganization of lipid raft microdomains and also in the dissociation of proteins [47] 
that are bound to the lipid raft. Cholesterol accumulation is known to be associated in many tumors, 
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including prostate cancer and oral cancer [48, 49], and dysregulated in lung and breast cancers [50, 
51]. Our data indicating that MDA-MB-231, that is highly aggressive tumor type representative, has 
an higher concentration of cholesterol in rafts and resistance to PUFA incorporation are in line to 
above cited reports. Li et al. demonstrated also that cholesterol depletion down regulate phospho-
Akt and phospho-ERK, which play critical roles in cell survival and induce apoptosis [52].  
A growing number of experimental observations demonstrates the incompatibility between 
cholesterol and DHA [53-55]. Saturated fatty acids, compared to PUFA, have a preferential affinity 
for cholesterol. This sterol condenses monolayers made from phospholipids containing a saturated 
chain in the sn-1 position and a saturated, oleic or -linoleic, but not DHA, in the sn-2 position. 
This relationship provides the basis for a lipid-driven mechanism for the lateral segregation of 
membrane elements into cholesterol-rich and -poor microdomains. For example, unfavourable 
interaction between cholesterol and PUFA chains has been clearly demonstrated by the exclusion of 
cholesterol from dipolyunsaturated phosphatidylcholine (PC) liposomes where it is forced to 
directly contact polyunsaturated chains. Studies using a variety of techniques including differential 
scanning calorimetry [56], 
1
H NMR and nuclear Overhauser enhancement spectroscopy with magic 
angle spinning, determination of partition coefficients [57], measurements of lateral compressibility 
[58], and fluorescence anisotropy [59], indicate that the poor affinity of DHA for cholesterol 
provides a lipid-driven mechanism for lateral phase separation of cholesterol-rich lipid 
microdomains from the surrounding bulk membrane. This could in principle alter the size, stability 
and distribution of cell surface lipid microdomains such as rafts. Indeed, evidences obtained from 
model membrane suggest that the energetically less favourable interaction between cholesterol and 
PUFA, especially DHA, promotes lateral phase segregation into sterol-poor/ PUFA-rich and sterol-
rich/saturated fatty acid-rich microdomains [60-62].  
Since lipid rafts are predominantly enriched in saturated fatty acids-containing sphingolipid and 
cholesterol, the incorporation of PUFA, especially DHA, determines in breast cancer cells a 
disruption of lipid rafts and a formation of the PUFA rich/cholesterol-poor domains.  
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On the contrary in our data AA increases cholesterol in MDA-MB-231 together with a slight 
increase of SM. Recently Pike and collaborators have demonstrated that lipid rafts are enriched in 
AA utilizing ESI/MS analysis [63]. This fatty acid is mainly linked to PE and PL-PE 
(plasmalogens) that are mainly in the inner membrane leaflet, while cholesterol and sphingomyelin 
are mainly in the outer leaflet. They speculate that this may represent a pool of AA for the 
generation of free AA in response to cell activation and subsequently increase of cell mediators 
such as PGE2. 
Our data on breast cancer cells are in agreement as AA represents the major PUFA of PLs in lipid 
rafts and is particularly concentrated in PE.  
The chemical physical features of fatty acids and related phospholipids are mainly influenced by 
their length and double bounds presence. Little variations may greatly influence their ability to 
interact in membranes with other lipids such as cholesterol. For instance there are many differences 
between phospholipids containing DHA (22:6) and DPA (22:5); the DHA chain with one additional 
double bond is more flexible at the methyl end and isomerizes with shorter correlation times. The 
loss of a single double bond from DHA to DPA results in a more even distribution of chain 
densities along the normal bilayer [64]. The different effects of DHA,  EPA and AA integrated in 
raft phospholipids on lipid content may be explained by their relative structural differences.  
A recent review of Shaikh [65] has hypothesized  a new model n-3 PUFA raft interaction with the 
formation of "declustered rafts". He raised also many question about the direct or indirect effects of 
n-3 PUFA on rafts. Our results demonstrate the direct incorporation of PUFA in phospholipids of 
detergent resistant membranes isolated with Triton X-100; when DHA is incorporated into raft it 
may induce the formation of what they define "declustered rafts" with reorganization of lipids and 
proteins. Preliminary results from our lab also demonstrate that DHA displaces EGFR from MDA-
MB-231 microdomains.  
In literature data on the synchronous effects of tamoxifen and n-3 PUFA are reported, pointing out 
the in vitro and in vivo capacity of omega-3, or their metabolites, to reduce cellular proliferation and 
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increase apoptosis. One of the mechanisms of action attributed to the apoptosis augment in 
DHA/EPA-treated MDA-MB-231 cells was impairment of Akt phosphorylation and NF-kB activity 
[66]. In line with this, in vivo studies showed an increased apoptotic index of MCF-7 cells injected 
into flaxseed oil-fed nude mice. This reduction was probably due to the down regulation of tyrosine 
kinase receptors such as EGFR and HER2, and the subsequent down regulation of Akt [67]. 
Interestingly some paper also reported the ability of tamoxifen to induce changes in physical and 
chemical properties of cell membrane inducing also changes in lipid composition and decreasing 
cholesterol content [68]. Our data suggest that DHA may act synergistically in this sense with 
tamoxifen. 
AFM analysis allowed us to characterize quantitatively morpho-dimensional changes induced by 
DHA incorporation in lipid rafts. In particular, for both the two cell lines (MCF-7 and MDA-MB-
231) the DHA treatment produced a decrease of the lipid rafts in the order of about 20%-30% (see 
Fig. 4). It is worth noticing that after DHA incorporation lipid rafts exhibit two different height 
ranges. In fact, some lipid rafts show an height of 4-4.5 nm such as the untreated ones, while several 
lipid rafts, in the order of about 20%, have a higher height of 6-6.5 nm (see Fig. 5).  
These changes might influence resident protein conformation turning on and/or off signalling 
proteins, and modulate cellular events. In fact acyl moieties of proteins partition in the cytoplasmic 
leaflet of the membrane lipid bilayer. Lipid alterations in the cytoplasmic lipid leaflet of membrane 
rafts would hence be particularly effective in displacing palmitoylated proteins.  
High resolution AFM imaging showed on MCF-7 lipid rafts, after DHA incorporation, pores in 
agreement, for dimensions and shape, with membrane proteins (see Fig. 6). A more accurate 
investigation, planned in the next future, and carried out using specific antibodies could confirm 
the nature of the observed structures and allow their identification. These preliminary results 
suggest that AFM could be an useful tool to characterize changes in the membrane protein content 
induced by n-3 PUFA treatment at single protein level.  
The data presented show an incorporation of PUFA with different specificity for the PL moiety. 
 19 
This may be relevant to the formation of PUFA metabolites (prostaglandins, prostacyclins, 
leukotrienes, resolvines and protectines) of phospholipids deriving second messengers and signal 
transduction activation. 
As an example phosphatidylinositol and phosphatidylcholine may act as sources of intracellular 
signals in response to extracellular signals which interact with receptors on the outer layer of 
plasma membrane. Hormones, or other extracellular signals, bind to the plasma membrane receptor 
which leads to activation of phospholipase C. Phospholipase C hydrolyses PI 4,5-
bisphosphate(PIP2) releasing inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DG). In 
consequence, IP3 (which is water soluble) causes release of calcium (Ca2+) from the endoplasmic 
reticulum. The combination of DG (which is lipid soluble and stays bound to the plasma membrane) 
and increased levels of Ca2+, together with membrane PS, lead to activation of the enzyme protein 
kinase C (PKC). This enzyme catalyses the phosphorylation of some cellular proteins, affecting 
cellular responses to the initial extracellular trigger. Fatty acids originating from the sn-2 glycerol 
carbon of PC greatly influence the activity of second messengers (DG). In this view the changes 
demonstrated in this paper with incorporation of fatty acids in PC, PS and PI phospholipids may 
contribute to explain the overall effects of PUFA reducing cell growth of breast cancer cells. 
Interestingly the treatment with n-3 PUFA decrease the content and change the fatty acid 
composition of PIP2 in Fat-1 CD4+ T-cells [69]. 
Moreover, EPA and DHA increasing the unsaturated state of phospholipids in lipid rafts of breast 
cancer cells, alter their physical-chemical properties. Many acylated proteins directly interact with 
membrane lipid bilayers by their saturated acyl moieties. Then we suggest that altered lipid 
composition of microdomains might determine the displacement of proteins from lipid rafts in n-3 
PUFA-treated cells with alteration of signal transduction 
In conclusion n-3 PUFA are able to modify lipid raft  biochemical and biophysical features leading 
to decrease of breast cancer cell proliferation probably through different mechanisms related to acyl 
chain length and unsaturation. While EPA may contribute to cell apoptosis mainly through decrease 
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of AA concentration in lipid raft phospholipids, indicating its influence in production of second 
messengers and PUFA metabolites, DHA may change the biophysical properties of lipid rafts 
decreasing the content of cholesterol and probably a redistribution of key proteins such as EGFR, 
ER-α and RAS. Future research will be dedicate to asses these hypotheses. 
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Figure Legends 
 
Figure 1- Characterization of Lipid Rafts from human breast cancer cells 
Post-nuclear homogenates from breast cancer cells were extracted using 1% of Triton X-100 and 
fractionated in 5-35% sucrose gradient as described in Methods. The purification of lipid rafts was 
demonstrated by the enrichment of sphingomyelin, cholesterol and gangliosideby HPTLC, in all 
fractions isolated from MDA-MB-231 (top) and MCF-7 (bottom) control cells (a,e) and treated with 
AA (b,f), EPA (c,g), DHA (d,h). Standards were spotted on the same plate (left). 
Equal amount of each fractions were subjected to western blot analyses against raft protein marker 
(flotillin-1) and non raft protein marker (clathrin).  
 
 
Figure 2- Effects of PUFA on sphingomyelin content of breast cancer cells lipid rafts 
Sphingomyelin content in lipid rafts of MCF7 (top) and MDA-MB-231 (bottom) breast cancer cells 
is obtained by HPLC-ELSD analysis. Data are represented as percentage of control ± SD (n=3). 
Control cells are not exposed to any exogenous fatty acid but incubated in the same conditions with 
the same ethanol concentration of treated cells. 
Vs respective CTR: * p < 0.05; **p < 0.01 
 
Figure 3- Effects of PUFA on cholesterol content of breast cancer cells  
Whole cell cholesterol and cholesterol in lipid rafts of breast cancer MCF7 (top) and MDA-MB-231 
(bottom) cells fractionated on sucrose gradient have been analysed by HPLC-ELSD. Cells were 
treated with AA (C20:4), EPA (C20:5), and DHA (C22:6) for 72hs. Measurements were performed 
in triplicate and data are presented as percentage of control ± SD (n = 3). Control cells are not 
exposed to any exogenous fatty acids but incubated in the same conditions with the same ethanol 
concentration of treated cells 
Vs respective CTR: * p < 0.05; **p < 0.01 
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Figure 4- AFM topographs before and after DHA treatment of MCF7 lipid rafts  
AFM topography images collected in contact mode in buffer solution of MCF7 lipid rafts before (a) 
and after (b) treatment with DHA (C22:6). Z range (from darkest to lightest): 50 nm. Scan area: 
10x10 µm
2
. 
 
Figure 5- Height profiles before and after DHA treatment of MCF7 lipid rafts  
Height profiles corresponding to the two black lines drawn in the AFM topography images reported 
in Fig 3. The DHA incorporated rafts (b) show two different height ranges: 4-4.5 nm and 6-6.5 nm 
(red arrows) while the control rafts (a) exhibit a constant height of about 4 nm (red arrows). While 
in the control samples lipid rafts exhibit a constant height of about 4 nm (see red arrows in a) as 
awaited for a membrane lipid bilayer, in DHA treated samples, lipid rafts show also the presence of 
a higher thickness (about 6 nm, see red arrows in b) likely induced by DHA incorporation effects. 
 
Figure 6- High resolution AFM topography  
(a) High resolution AFM topography image (bottom) obtained visualizing a small region (300x300 
nm
2
) on the surface of a lipid raft of DHA treated MCF7 cells (top). Several pores with a diameter 
of about 9 nm (red arrows in the height profile) are clearly visible on the lipid raft surface. (b) 
Histogram of the lateral dimensions of the membrane pores visualized on MCF7 lipid rafts after 
DHA treatment. The dimensions have been measured along (horizontal) and perpendicularly 
(vertical) to the scan direction. The diameters of the visualized pores appear to be in good 
agreement with the dimensions of membrane proteins observed by AFM. 
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